Characterization of E. coli-specific T cells in Crohn's disease

克罗恩病中大肠杆菌特异性 T 细胞的表征

基本信息

项目摘要

PROJECT SUMMARY/ABSTRACT Several lines of evidence have implicated T cells in the pathogenesis of Crohn's disease, an uncontrolled inflammatory condition of the intestines in which immune cells overreact to the bacteria that live there. Previous studies of antigen-nonspecific T cells in Crohn's disease have not identified overall differences in them that would explain this over reactivity. However, we have recently identified CD4 T cells of the immune system that can react to a peptide from protein antigen (OmpC) made by one such bacteria (E. coli), to which antibodies are commonly seen only in people with Crohn's disease. We found that these OmpC-specific cells make IL-10 unless they come from Crohn's disease patients, and hypothesize that this defect plays a central role in the inflammation of Crohn's disease. IL-10 is a cytokine that clearly plays a central role in limiting inflammation in the intestines, because mice without the IL-10 gene and humans born with a mutation in the receptor for IL-10 both quickly develop severe enterocolitis, resembling Crohn's disease. The overall goal of the studies proposed here is to determine why these gut flora antigen-specific T cells fail to make IL-10 in Crohn's disease, as a mechanism by which tolerance to gut flora is lost in this condition. The novel approach is to integrate single cell gene expression and epigenetic analyses in these OmpC-specific T cells we can isolate with MHC-II tetramers. The hypothesis will be addressed in two Specific Aims with genome-wide expression differences correlated with IL-10 expression in Aim 1, and an epigenetic basis for failed IL-10 expression in Crohn's disease to be revealed in Aim 2. Together these studies will advance our understanding of abnormal IL-10 regulation by gut microbial antigen-specific T cells in Crohn's disease, and provide the foundation for determining how such a defect contributes to disease pathogenesis.
项目摘要/摘要 有几条证据表明T细胞与克罗恩病的发病有关,克罗恩病是一种未受控制的 肠道的一种炎症状态,免疫细胞对生活在那里的细菌反应过度。 以前对克罗恩病的抗原非特异性T细胞的研究还没有发现在 他们可以解释这种反应过度的现象。然而,我们最近发现了免疫的CD4T细胞 一种能与由这样一种细菌(大肠杆菌)产生的蛋白质抗原(OMPC)中的多肽发生反应的系统,对其 抗体通常只出现在克罗恩病患者身上。我们发现这些OMPC特异性细胞 产生IL-10,除非他们来自克罗恩病患者,并假设这种缺陷在 在克罗恩病炎症中的作用。IL-10是一种细胞因子,显然在限制 肠道炎症,因为没有IL-10基因的小鼠和出生时携带IL-10基因突变的人类 IL-10的受体都会迅速发展成严重的小肠结肠炎,类似于克罗恩病。的总目标是 这里提出的研究是为了确定为什么这些肠道菌群抗原特异的T细胞无法在 克罗恩病,是一种在这种情况下对肠道菌群失去耐受性的机制。新方法 是在这些OMPC特异性T细胞中整合单细胞基因表达和表观遗传学分析,我们可以 用MHC-II四聚体分离。这一假说将在全基因组范围内以两个特定的目标来解决 AIM 1的表达差异与IL-10的表达相关,并为失败的IL-10的表观遗传学基础 在克罗恩病中的表达将在AIM 2中揭示。这些研究将共同推进我们的理解 克隆氏病患者肠道微生物抗原特异性T细胞对IL-10的异常调节 为确定这种缺陷如何导致疾病发病机制奠定了基础。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

James Daniel Lord其他文献

James Daniel Lord的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('James Daniel Lord', 18)}}的其他基金

Characterization of E. coli-specific T cells in Crohn's disease
克罗恩病中大肠杆菌特异性 T 细胞的表征
  • 批准号:
    10452471
  • 财政年份:
    2022
  • 资助金额:
    $ 21.66万
  • 项目类别:
Intestinal Dendritic Cell Modulation of Regulatory T Cell Function in IBD
IBD 中调节性 T 细胞功能的肠道树突状细胞调节
  • 批准号:
    8141666
  • 财政年份:
    2008
  • 资助金额:
    $ 21.66万
  • 项目类别:
Intestinal Dendritic Cell Modulation of Regulatory T Cell Function in IBD
IBD 中调节性 T 细胞功能的肠道树突状细胞调节
  • 批准号:
    7808332
  • 财政年份:
    2008
  • 资助金额:
    $ 21.66万
  • 项目类别:
Intestinal Dendritic Cell Modulation of Regulatory T Cell Function in IBD
IBD 中调节性 T 细胞功能的肠道树突状细胞调节
  • 批准号:
    7513622
  • 财政年份:
    2008
  • 资助金额:
    $ 21.66万
  • 项目类别:
Intestinal Dendritic Cell Modulation of Regulatory T Cell Function in IBD
IBD 中调节性 T 细胞功能的肠道树突状细胞调节
  • 批准号:
    8077443
  • 财政年份:
    2008
  • 资助金额:
    $ 21.66万
  • 项目类别:
Intestinal Dendritic Cell Modulation of Regulatory T Cell Function in IBD
IBD 中调节性 T 细胞功能的肠道树突状细胞调节
  • 批准号:
    8317680
  • 财政年份:
    2008
  • 资助金额:
    $ 21.66万
  • 项目类别:
Intestinal Dendritic Cell Modulation of Regulatory T Cell Function in IBD
IBD 中调节性 T 细胞功能的肠道树突状细胞调节
  • 批准号:
    7676870
  • 财政年份:
    2008
  • 资助金额:
    $ 21.66万
  • 项目类别:

相似海外基金

Development of small molecule inhibitors as anti-inflammatory agents and antidotes for arsenicals
开发作为抗炎剂和砷解毒剂的小分子抑制剂
  • 批准号:
    10727507
  • 财政年份:
    2023
  • 资助金额:
    $ 21.66万
  • 项目类别:
Discovery of New Anti-Inflammatory Agents to Treat COPD
发现治疗慢性阻塞性肺病的新型抗炎药
  • 批准号:
    9194162
  • 财政年份:
    2016
  • 资助金额:
    $ 21.66万
  • 项目类别:
Synthesis of anti-inflammatory agents and their structure-activity relationships studies
抗炎药的合成及其构效关系研究
  • 批准号:
    496858-2016
  • 财政年份:
    2016
  • 资助金额:
    $ 21.66万
  • 项目类别:
    University Undergraduate Student Research Awards
NAAA Inhibitors as Anti-inflammatory Agents, Phase II
NAAA 抑制剂作为抗炎剂,II 期
  • 批准号:
    9201955
  • 财政年份:
    2015
  • 资助金额:
    $ 21.66万
  • 项目类别:
Novel flavonoids as anti-inflammatory agents in alcoholism
新型黄酮类化合物作为酒精中毒的抗炎剂
  • 批准号:
    8251289
  • 财政年份:
    2014
  • 资助金额:
    $ 21.66万
  • 项目类别:
TLR-7 Agonists as Targeted Anti-inflammatory Agents in Arthritis
TLR-7 激动剂作为关节炎的靶向抗炎药
  • 批准号:
    8302750
  • 财政年份:
    2012
  • 资助金额:
    $ 21.66万
  • 项目类别:
Design and in vivo delivery of novel anti-inflammatory agents
新型抗炎剂的设计和体内递送
  • 批准号:
    267940
  • 财政年份:
    2012
  • 资助金额:
    $ 21.66万
  • 项目类别:
    Operating Grants
Development of inlammasome inhibitors to be used as anti-inflammatory agents
开发用作抗炎剂的inlammasome抑制剂
  • 批准号:
    8403458
  • 财政年份:
    2012
  • 资助金额:
    $ 21.66万
  • 项目类别:
Development of inlammasome inhibitors to be used as anti-inflammatory agents
开发用作抗炎剂的inlammasome抑制剂
  • 批准号:
    8549297
  • 财政年份:
    2012
  • 资助金额:
    $ 21.66万
  • 项目类别:
TLR-7 Agonists as Targeted Anti-inflammatory Agents in Arthritis
TLR-7 激动剂作为关节炎的靶向抗炎药
  • 批准号:
    8472443
  • 财政年份:
    2012
  • 资助金额:
    $ 21.66万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了